| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3851453 | American Journal of Kidney Diseases | 2009 | 8 Pages |
Abstract
A large population of stable renal transplant recipients who are at high risk of the development of CVD (both de novo and recurrent) has been recruited into the Folic Acid for Vascular Outcome Reduction in Transplantation Trial and are likely to experience a sufficient number of events to address the primary hypothesis of the trial.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Andrew G. MD, Myra A. PhD, Lawrence MD, Paul F. ScD, John W. PhD, Andrew S. MD, Joyce L. MA, MPH, Renee Y. BS, Marc A. MD, PhD, Jacob PhD, FAVORIT Study Investigators FAVORIT Study Investigators,